CVR: 45364577
Akasi Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2025. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Walden Emil Bjørn-Yoshimoto and Helena Safavi-Hemami. The company is owned by Walden Holding ApS, Sophie Holding ApS and Venimic LLC. In 2025, the company reported revenue of DKK 1,026,737 and a net result of DKK -1,626,789. Equity amounted to DKK -1,570,789.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at udføre forskning, udvikling, produktion og handel med lægemidler, samt at udøve enhver aktivitet, der har direkte eller indirekte forbindelse hermed.
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringCompared to 1.051 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Akasi Pharma ApS has published its annual report for 2025. Revenue came to DKK 1,026,737, and the net result was DKK -1,626,789.
As of October 17, 2025, Sophie Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 10%.
As of October 17, 2025, is registered as an owner of Akasi Pharma ApS with an ownership share of 25%.
As of January 29, 2025, Walden Emil Bjørn-Yoshimoto is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Helena Safavi-Hemami is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Walden Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 50%.
Akasi Pharma ApS was founded on January 29, 2025.
Companies in the same industry and area
CVR 45436497
CVR 46543912
CVR 40766383
CVR 42731323
CVR 38599119
companydata.dk